【Zephyr AI完成1.1亿美元A轮融资，引领精准医疗AI新里程】近日，精准医疗领域的AI算法初创公司Zephyr AI宣布成功获得1.11亿美元的A轮融资，此轮融资由知名投资机构Revolution Growth领投，礼来公司、Jeff Skoll和EPIQ Capital Group等重量级投资者跟投。这一消息标志着Zephyr AI在医疗技术行业的影响力和潜力得到了广泛认可。
Zephyr AI公司专注于开发快速且具有可解释性的AI解决方案，以推动精准医疗的进步。通过其创新技术，Zephyr AI旨在提高医疗诊断的精确度和效率，为患者提供更为个性化和精准的治疗方案。此次大规模融资将为Zephyr AI提供充足的资金，加速其产品研发，进一步提升其在医疗AI领域的领先地位。
Revolution Growth等投资方的加入，不仅为Zephyr AI带来了资金支持，也将为其带来丰富的行业资源和战略指导。礼来公司作为全球知名的制药企业，其参与投资也显示出对Zephyr AI技术在药物研发和临床应用方面的高度期待。
Zephyr AI的A轮融资成功，预示着AI技术在医疗领域的深度应用正不断加速，有望开启精准医疗的新篇章。随着科技与医疗的深度融合，我们期待Zephyr AI能够为全球医疗健康事业带来革命性的变革。
英语如下：
**News Title:** “Zephyr AI Secures $110M in Funding, Revolution Growth and Eli Lilly Drive Precision Medicine AI Forward”
**Keywords:** Zephyr AI, Precision Medicine, Series A Funding
**News Content:** **Zephyr AI Closes $110M Series A Financing, Paving the Way for AI-Powered Precision Medicine** Recently, Zephyr AI, an AI algorithm startup in the precision medicine field, announced that it has successfully raised $111 million in its Series A funding round. The round was led by prominent investment firm Revolution Growth, with significant participation from Eli Lilly, Jeff Skoll, and EPIQ Capital Group, among others. This development signifies a broad endorsement of Zephyr AI’s influence and potential in the healthcare technology industry.
Specializing in the development of fast and explainable AI solutions, Zephyr AI aims to advance precision medicine by enhancing the accuracy and efficiency of medical diagnoses. Through its innovative technology, the company strives to provide more personalized and targeted treatment options for patients. The substantial funding will enable Zephyr AI to accelerate its product development, solidifying its position at the forefront of the medical AI sector.
The involvement of investors like Revolution Growth not only brings financial backing but also invaluable industry resources and strategic guidance. Eli Lilly’s participation as a renowned global pharmaceutical company underscores its high expectations for Zephyr AI’s technology in drug development and clinical applications.
The successful Series A funding for Zephyr AI signals an acceleration in the deep integration of AI technology in healthcare, poised to usher in a new era of precision medicine. As technology and healthcare converge, we anticipate Zephyr AI to bring transformative changes to the global healthcare landscape.
【来源】https://www.businesswire.com/news/home/20240312475536/en/Zephyr-AI-Raises-111-Million-in-Series-A-Financing
Views: 1